Trial reportAntimicrobial agents and chemotherapy2002
Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens.
Trial report in Antimicrobial agents and chemotherapy, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers.Malaria journal · 2016Trial
- Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.Antimicrobial agents and chemotherapy · 2012Trial
- Orally formulated artemisinin in healthy fasting Vietnamese male subjects: a randomized, four-sequence, open-label, pharmacokinetic crossover study.Clinical therapeutics · 2011Trial
- First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone.Antimicrobial agents and chemotherapy · 2008Trial
- Semi-mechanistic pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of artemisinin.British journal of clinical pharmacology · 2005Trial
- A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.British journal of clinical pharmacology · 2005Trial
- CYP3A4-mediated metabolism of artemisinin to 10β-hydroxyartemisinin with comparable anti-malarial potency.Malaria journal · 2024Article
- Antimicrobial Susceptibility Testing for ThreeMicrobiology spectrum · 2023Article
- Complexity of Plasmodium falciparum infection and genetic variations associated with differences in parasite clearance time in two Malian villages.Research square · 2023Article
- Scoping Review of Antimalarial Drug Candidates in Phase I and II Drug Development.Antimicrobial agents and chemotherapy · 2022Article
- Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.Frontiers in pharmacology · 2021Review
- The gender-related variability in the pharmacokinetics and antiplasmodial activity of naphthoquine in rodents.Malaria journal · 2020Article
- Artemisinin Prevents Glutamate-Induced Neuronal Cell Death Via Akt Pathway Activation.Frontiers in cellular neuroscience · 2018Article
- Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers.The Journal of antimicrobial chemotherapy · 2016Article
- Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells.Molecular carcinogenesis · 2016Article
- Pharmacokinetic study of gallocatechin-7-gallate from Pithecellobium clypearia Benth. in rats.Acta pharmaceutica Sinica. B · 2016Article
- Preliminary Case Series of Artemisinin for Prostate Cancer in a Naturopathic Practice.Journal of restorative medicine · 2015Article
- Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination.Malaria journal · 2014Article
- Article
- An investigation of the auto-induction of and gender-related variability in the pharmacokinetics of dihydroartemisinin in the rat.Malaria journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The immediate efficacies of two oral dosage regimens of artemisinin were investigated in 77 male and female adult Vietnamese falciparum malaria patients randomly assigned to treatment with either 500 mg of artemisinin daily for 5 days (group A; n = 40) or artemisinin at a dose of 100 mg per day for 2 days, with the dose increased to 250 mg per day for 2 consecutive days and with a final dose of 500 mg on the fifth day (group B; n = 37). Parasitemia was monitored every 4 h. The average parasite clearance time was longer in group B than in group A (means +/- standard deviations, 50 +/- 23 and 34 +/- 14 h, respectively; P < 0.01). Artemisinin concentrations in saliva samples obtained on days 1 and 5 were quantified by high-performance liquid chromatography. The average oral clearance, based on saliva drug concentrations in group B patients, was twofold higher than that in group A patients on day 1 (P < 0.01), with no differences in drug half-lives (P = 0.40), indicating a saturable first-pass metabolism. Female patients had higher oral clearance values on day 1. Artemisinin's pharmacokinetic parameters were similar on day 5 in both groups, although a significant increase in oral clearance from day 1 to day 5 was evident. Thus, artemisinin exhibited both dose- and time-dependent pharmacokinetics. The escalating dose studied did not result in higher artemisinin concentrations toward the end of the treatment period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.